PDS Biotechnology Corp reports results for the quarter ended in September - Earnings Summary

PDS Biotechnology

14/11/2022 14:32

* PDS Biotechnology Corp  PDSB.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in September.
The mean expectation of eight analysts for the quarter was for a
loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * PDS Biotechnology Corp's reported EPS for the quarter was
a loss
of 26 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * PDS Biotechnology Corp shares had risen by 88.6% this
quarter and lost 30.9% so far this year.
    * The company reported a quarterly loss of $7.42 million.
    * Wall Street's median 12-month price target for PDS
Biotechnology
Corp is $15.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.28          -0.26          Beat
 Jun. 30 2022      -0.28          -0.20          Beat
 Mar. 31 2022      -0.22          -0.32          Missed
 Dec. 31 2021      -0.24          -0.22          Beat